Eicosanoids and renal vascular function in diseases

Clinical Science

Volumn 111, Issue 1, 2006, Pages 21-34

  Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cyclo oxygenase (COX); Cytochrome P450 (CYP450); Epoxyeicosatrienoic acid (EET); Hypertension; Kidney; Metabolic syndrome; Obesity

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID DERIVATIVE; BAICALEIN; CINNAMIC ACID DERIVATIVE; CINNAMYL 3,4 DIHYDROXYCYANOCINNAMATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; ICOSANOID; ILOPROST; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PHENIDONE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; THROMBOXANE SYNTHASE; U 44169; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EDEMA; EXPERIMENTAL MODEL; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STROKE;

DIABETES MELLITUS; EICOSANOIDS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, ACUTE; METABOLIC SYNDROME X; RENAL CIRCULATION;

EID: 33745797993     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050251     Document Type: Review

References (159)

1. Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185
2. Imig, J. D. (2000) Eicosanoid regulation of the renal vasculature. Am. J. Physiol. Renal Physiol. 279, F965-F981
3. Quilley, J., Bell-Quilley, C. P. and McGiff, J. C. (1995) Eicosanoids and hypertension. In Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn (J. H. Laragh and B. M. Brenner, eds.), pp. 963-982, Raven Press, New York
4. Imig, J. D., Zhao, X., Dey, A. and Shaw, M. (2005) CYP450, COX-2 and obesity related renal damage. Toxicol. Mechan. Methods 15, 125-136
5. Cheng, H. F. and Harris, R. C. (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension 43, 525-530
6. Breyer, M. D. and Breyer, R. M. (2000) Prostaglandin receptors: their role in regulating renal function. Curr. Opin. Nephrol. Hypertens. 9, 23-29
7. Breyer, M. D. and Breyer, R. M. (2000) Prostaglandin E receptors and the kidney. Am. J. Physiol. Renal Physiol. 279, F12-F23
8. 2 receptors in control of murine renal hemodynamics. Am. J. Physiol. Heart Circ. Physiol. 280, H327-H333
9. 4 receptors. Circ. Res. 86, 663-670
10. 2 receptors to renal microvascular reactivity in mice. Am. J. Physiol. Renal Physiol. 283, F415-F422
11. Chaudhari, A., Gupta, S. and Kirschenbaum, M. A. (1990) Biochemical evidence for PGI2 and PGE2 receptors in the rabbit renal preglomerular microvasculature. Biochim. Biophys. Acta 1053, 156-161
12. s protein interactions in isolated renal resistance arterioles of spontaneously hypertensive rats. Hypertension 34, 1134-1140
13. Jensen, B. L., Schmid, C. and Kurtz, A. (1996) Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am. J. Physiol. 271, F659-F669
14. Schweda, F., Klar, J., Narumiya, S., Nusing, R. M. and Kurtz, A. (2004) Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am. J. Physiol. Renal Physiol. 287, F427-F433
15. Chatziantoniou, C. and Arendshorst, W. J. (1992) Renal vascular reactivity to vasodilator prostaglandins in genetically hypertensive rats. Am. J. Physiol. 262, F124-F130
16. Chatziantoniou, C. and Arendshorst, W. J. (1992) Prostaglandin interactions with angiotensin, norepinephrine, and thromboxane in rat renal vasculature. Am. J. Physiol. 262, F68-F76
17. Imig, J. D. and Deichmann, P. C. (1997) Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. Am J. Physiol. 273, F274-F282
18. Navar, L. G., Inschol E. W., Majid, S. A., Imig, J. D., Harrison-Bernard, L. M. and Mitchell, K. D. (1996) Paracrine regulation of the renal microcirculation. Physiol. Rev. 76, 425-536
19. Purdy, K. E. and Arendshorst, W. J. (1999) Prostaglandins buffer ANG II-mediated increases in cytosolic calcium in preglomerular VSMC. Am. J. Physiol. 277, F850-F858
20. Purdy, K. E. and Arendshorst, W. J. (2001) Iloprost inhibits inositol-1,4,5-trisphosphate-mediated calcium mobilization stimulated by angiotensin II in cultured preglomerular vascular smooth muscle cells. J. Am. Soc. Nephrol. 12, 19-28
21. Miyamoto, M., Yamada, N., Ikezawa, S. et al. (2003) Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br. J. Pharmacol. 140, 889-894
22. Jin, R. C., Voetsch, B. and Loscalzo, J. (2005) Endogenous mechanisms of inhibition of platelet function. Microcirculation 12, 247-258
23. Tajiri, Y., Umeda, F., Inoguchi, T. and Nawata, H. (1994) Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. J. Diabetes Complications 8, 126-132
24. Umeda, F., Kuroki, T. and Nawata, H. (1995) Prostaglandins and diabetic nephropathy. J. Diabetes Complications 9, 334-336
25. Katayama, S., Inaba, M., Maruno, Y. et al. (1990) Increased renal TXA2 synthesis in diabetes mellitus: simultaneous determination of urinary TXB2 and 2,3-dinor-TXB2. Prostaglandins Leukotriene Essent. Fatty Acids 39, 47-51
26. Patrono, C., Ciabattoni, G., Pugliese, F., Pierucci, A., Blair, I. A. and FitzGerald, G. A. (1986) Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77, 590-594
27. Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C. and Ware, J. A. (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem. 269, 19256-19261
28. Offermanns, S., Laugwitz, K. L., Spicher, K. and Schultz, G. (1994) G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc. Natl. Acad. Sci. U.S.A. 91, 504-508
29. Hayashi, K., Loutzenhiser, R. and Epstein, M. (1997) Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole. J. Am. Soc. Nephrol. 8, 25-31
30. Imig, J. D. (2000) Epoxygenase metabolites. Epithelial and vascular actions. Mol. Biotechnol. 16, 233-251
31. Capdevila, J. H. and Falck, J. R. (2001) The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem. Biophys. Res. Commun. 285, 571-576
32. Stec, D. E., Flasch, A., Roman, R. J. and White, J. A. (2003) Distribution of cytochrome P-450 4A and 4F isoforms along the nephron in mice. Am. J. Physiol. Renal Physiol. 284, F95-F102
33. Alonso-Galicia, M., Drummond, H. A., Reddy, K. K., Falck, J. R. and Roman, R. J. (1997) Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29, 320-325
34. Imig, J. D., Zou, A. P., Stec, D. E., Harder, D. R., Falck, J. R. and Roman, R. J. (1996) Formation and actions ot 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am. J. Physiol. 270, R217-R227
35. Ma, Y. H., Gebremedhin, D., Schwartzman, M. L. et al. (1993) 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ. Res. 72, 126-136
36. Busse, R., Edwards, G., Feletou, M., Fleming, I., Vanhoutte, P. M. and Weston, A. H. (2002) EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23, 374-380
37. Campbell, W. B., Gebremedhin, D., Pratt, P. F. and Harder, D. R. (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78, 415-423
38. Imig, J. D., Inscho, E. W., Deichmann, P. C., Reddy, K. M. and Falck, J. R. (1999) Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 33, 408-413
39. Imig, J. D., Navar, L. G., Roman, R. J., Reddy, K. K. and Falck, J. R. (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 7, 2364-2370
40. Imig, J. D., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J. Vasc. Res. 38, 247-255
41. Fulton, D., McGiff, J. C. and Quilley, J. (1992) Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br. J. Pharmacol. 107, 722-725
42. Zhao, X. and Imig, J. D. (2003) Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr. Drug Metab. 4, 73-84
43. Brash, A. R. (1999) Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274, 23679-23682
44. Yamamoto, S. (1992) Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta 1128, 117-131
45. Funk, C. D., Keeney, D. S., Oliw, E. H., Boeglin, W. E. and Brash, A. R. (1996) Functional expression and cellular localization of a mouse epidermal lipoxygenase. J. Biol. Chem. 271, 23338-23344
46. Natarajan, R. and Nadler, J. E. (2004) Lipid inflammatory mediators in diabetic vascular disease. Arterioscler., Thromb., Vasc. Biol. 24, 1542-1548
47. Yiu, S. S., Zhao, X., Inscho, E. W. and Imig, J. D. (2003) 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. J. Lipid Res. 44, 2391-2399
48. Katoh, T., Takahashi, K., DeBoer, D. K., Serhan, C. N. and Badr, K. F. (1992) Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. Am. J. Physiol. 263, F436-F442
49. Kieran, N. E., Maderna, P. and Godson, C. (2004) Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65, 1145-1154
50. Badr, K. E, DeBoer, D. K., Schwartzberg, M. and Serhan, C. N. (1989) Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc. Natl. Acad. Sci. U.S.A. 86, 3438-3442
51. Leonard, M. O., Hannan, K., Burne, M. J. et al. (2002) 15-Epi-16-(para-fluorophenoxy)-lipoxin A4-methyl ester, a synthetic analogue of 15-epi-lipoxin A4, is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13, 1657-1662
52. Chatziantoniou, C., Ruan, X. and Arendshorst, W. J. (1993) Interactions of cAMP-mediated vasodilators with angiotensin II in rat kidney during hypertension. Am. J. Physiol. 265, F845-F852
53. Chatziantoniou, C., Daniels, F. H. and Arendshorst, W. J. (1990) Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats. Am. J. Physiol. 259, F372-F382
54. Kawada, N., Dennehy, K., Solis, G. et al. (2004) TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am. J. Physiol. Renal Physiol. 287, F753-F759
55. Wilcox, C. S. and Welch, W. J. (1990) Thromboxane mediation of the pressor response to infused angiotensin II. Am. J. Hypertens. 3, 242-249
56. Wilcox, C. S. and Welch, W. J. (2003) Thromboxane synthase and TP receptor mRNA in rat kidney and brain: effects of salt intake and ANG II. Am. J. Physiol. Renal Physiol. 284, F525-F531
57. Qi, Z., Hao, C. M., Langenbach, R. I. et al. (2002) Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110, 61-69
58. Cheng, H. F., Wang, C. J., Moeckel, G. W., Zhang, M. Z., McKanna, J. A. and Harris, R. C. (2002) Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model or diabetes and hypertension. Kidney Int. 62, 929-939
59. Fujino, T., Nakagawa, N., Yuhki, K. et al. (2004) Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin 12 receptor IP. J. Clin. Invest. 114, 805-812
60. Suganami, T., Mori, K., Tanaka, I. et al. (2003) Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42, 1183-1190
61. Schwartzman, M. E., da Silva, J. E., Lin, F., Nishimura, M. and Abraham, N. G. (1996) Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Nephron 73, 652-663
62. Wang, M. H., Zhang, E, Marji, J., Zand, B. A., Nasjletti, A. and Laniado-Schwartzman, M. (2001) CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 280, R255-R261
63. Stec, D.E., Trolliet, M. R., Krieger, J. E., Jacob, H. J. and Roman, R. J. (1996) Renal cytochrome P4504A activity and salt sensitivity in spontaneously hypertensive rats. Hypertension 27, 1329-1336
64. Holla, V. R., Adas, F., Imig, J. D. et al. (2001) Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc. Natl. Acad. Sci. U.S.A. 98, 5211-5216
65. Laffer, C. L., Lamado-Schwartzman, M., Wang, M. H., Nasjletti, A. and Elijovich, F. (2003) 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension. Hypertension 41, 703-708
66. Laffer, C. L., Laniado-Schwartzman, M., Wang, M. H., Nasjletti, A. and Elijovich, F. (2003) Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 107, 574-578
67. Gainer, J. V., Bellamine, A., Dawson, E. P. et al. (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111, 63-69
68. Ward, N. C., Rivera, J., Hodgson, J. et al. (2004) Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110, 438-443
69. Ward, N. C., Puddey, I. B., Hodgson, J. M., Beilin, L. J. and Croft, K. D. (2005) Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radical Biol. Med. 38, 1032-1036
70. Kim, I. H., Morisseau, C., Watanabe, T. and Hammock, B. D. (2004) Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47, 2110-2122
71. Morisseau, C., Goodrow, M. H., Dowdy, D. et al. (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. U.S.A. 96, 8849-8854
72. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694
73. Jung, O., Brandes, R. P., Kim, I. H. et al. (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765
74. Fornage, M., Boerwinkle, E., Doris, P. A., Jacobs, D., Liu, K. and Wong, N. D. (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335-339
75. Sato, K., Emi, M., Ezura, Y. et al. (2004) Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J. Hum. Genet. 49, 29-34
76. Imig, J. D., Zhao, X., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J. Hypertens. 19, 983-992
77. Zhao, X., Yamamoto, T., Newman, J. W. et al. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15, 1244-1253
78. Kaergel, E., Muller, D. N., Honeck, H. et al. (2002) P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40, 273-279
79. Muller, D. N., Theuer, J., Shagdarsuren, E. et al. (2004) A peroxisome proliferator-activated receptor-α activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am. J. Pathol. 164, 521-532
80. Yu, Z., Xu, F., Huse, L. M. et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992-998
81. Stern, N., Yanagawa, N., Saito, F. et al. (1993) Potential role of 12 hydroxyeicosatetraenoic acid in angiotensin II-induced calcium signal in rat glomerulosa cells. Endocrinology 133, 843-847
82. Sasaki, M., Hori, M. T., Hino, T., Golub, M. S. and Tuck, M. E. (1997) Elevated 12-lipoxygenase activity in the spontaneously hypertensive rat. Am. J. Hypertens. 10, 371-378
83. Gonzalez-Nunez, D., Claria, J., Rivera, F. and Poch, E. (2001) Increased levels of 12S-HETE in patients with essential hypertension. Hypertension 37, 334-338
84. DelliPizzi, A., Guan, H., Tong, X., Takizawa, H. and Nasjletti, A. (2000) Lipoxygenase-dependent mechanisms in hypertension. Clin. Exp. Hypertens. 22, 181-192
85. Nozawa, K., Tuck, M. L., Golub, M., Eggena, P., Nadler, J. L. and Stern, N. (1990) Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am. J. Physiol. 259, H1774-H1780
86. Lin, L., Balazy, M., Pagano, P. J. and Nasjletti, A. (1994) Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats. Relation to lipoxygenase and prostacyclin synthase activities. Circ. Res. 74, 197-205
87. Saito, F., Hori, M. T., Ideguchi, Y. et al. (1992) 12-Lipoxygenase products modulate calcium signals in vascular smooth muscle cells. Hypertension 20, 138-143
88. Anning, P. B., Coles, B., Bermudez-Fajardo, A. et al. (2005) Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-hpoxygenase knockout mice. Am. J. Pathol. 166, 653-662
89. Coffey, M. J., Natarajan, R., Chumley, P. H. et al. (2001) Catalytic consumption of nitric oxide by 12/15-lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. Proc. Natl. Acad. Sci. U.S.A. 98, 8006-8011
90. McGiff, J. C. and Quilley, J. (1999) 20-HETE and the kidney: resolution of old problems and new beginnings. Am. J. Physiol. 277, R607-R623
91. Caron, N., El Hajjam, A., Decleves, A. E., Joly, E., Falck, J. R. and Kramp, R. (2004) Changes in renal haemodynamics induced by indomethacin in the rat involve cytochrome P450 arachidonic acid-dependent epoxygenases. Clin. Exp. Pharmacol. Physiol. 31, 683-690
92. Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. and D'Agati, V. D. (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498-1509
93. Sowers, J. R. and Epstein, M. (1995) Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 26, 869-879
94. Vivian, E. M. and Rubinstein, G. B. (2002) Pharmacologic management of diabetic nephropathy. Clin. Ther. 24, 1741-1756
95. Komers, R., Lindsley, J. N., Oyama, T. T. et al. (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107, 889-898
96. Zatz, R. and Fujihara, C. K. (2002) Cyclooxygenase-2 inhibitors: will they help us prevent diabetic nephropathy? Kidney Int. 62, 1091-1092
97. Zatz, R. and Fujihara, C. K. (2002) Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. J. Hypertens. Suppl. 20, S37-S44
98. Dey, A., Marie, C., Kaesemeyer, W. H. et al. (2004) Rofecoxib decreases renal injury in obese Zucker rats. Clin. Sci. 107, 561-570
99. Dey, A., Williams, R. S., Pollock, D. M. et al. (2004) Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes. Res. 12, 1278-1289
100. Patrono, C., Ciabattoni, G., Simonetti, B. M. and Pierucci, A. (1986) Alterations of renal arachidonate metabolism in chronic glomerular disease. Adv. Prostaglandin, Thromboxane, Leukotriene Res. 16, 199-204
101. Cosentino, F., Eto, M., De Paolis, P. et al. (2003) High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107, 1017-1023
102. Shanmugam, N., Gaw Gonzalo, I. T. and Natarajan, R. (2004) Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 53, 795-802
103. Shanmugam, N., Kim, Y. S., Lanting, L. and Natarajan, R. (2003) Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 278, 34834-34844
104. Fang, C., Jiang, Z. and Tomlinson, D. R. (1997) Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes; effects of treatment with evening primrose oil or an aldosc reductase inhibitor on COX-1 mRNA levels. Prostaglandins Leukotrienes Essent. Fatty Acids 56, 157-163
105. Craven, P. A. and DeRubertis, F. R. (1989) Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozocin-induced diabetes. J. Lab. Clin. Med. 113, 674-681
106. Metz, S. A., Robertson, R. P. and Fujimoto, W. Y. (1981) Inhibition of prostaglandin E synthesis augments glucose-induced insulin secretion in cultured pancreas. Diabetes 30, 551-557
107. Okumura, M., Imanishi, M., Yamashita, T. et al. (2000) Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes. Life Sci. 66, 371-377
108. Ajayi, A. A., Ogungbade, G. O., Hercule, H. C., Oyekan, A. O. and Mutembei, L. (2004) Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA2 mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats. Diabetes Res. Clin. Pract. 63, 155-169
109. Kirschenbaum, M. A. (1986) Prostanoids and renal failure. A hypothetical role for prostanoids in progressive renal disease. Contrib. Nephrol. 50, 36-45
110. Kirschenbaum, M. A. and Chaudhari, A. (1986) Effect of experimental diabetes on glomerular filtration rate and glomerular prostanoid production in the rat. Miner. Electrolyte Metab. 12, 352-355
111. Komers, R. and Anderson, S. (2001) Treatment of hypertension in diabetic patients with nephropathy. Curr. Diab. Rep. 1, 251-260
112. Komers, R., Anderson, S. and Epstein, M. (2001) Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kidney Dis. 38, 1145-1157
113. Hayashi, K., Epstein, M., Loutzenhiser, R. and Forster, H. (1992) Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J. Am. Soc. Nephrol. 2, 1578-1586
114. Uriu, K., Kaizu, K., Hashimoto, O., Komine, N. and Etoh, S. (1994) Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats. Kidney Int. 45, 794-802
115. Masumura, H., Kunitada, S., Irie, K., Ashida, S. and Abe, Y. (1992) A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. Eur. J. Pharmacol. 210, 163-172
116. Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N. and Breyer, M. D. (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94, 2504-2510
117. Gambaro, G. and Perazella, M. A. (2003) Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselectivc cyclooxygenase inhibitors. J. Intern. Med. 253, 643-652
118. Komhoff, M., Grone, H. J., Klein, T., Seyberth, H. W. and Nusing, R. M. (1997) Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol. 272, F460-F468
119. Nantel, F., Meadows, E., Denis, D., Connolly, B., Metters, K. M. and Giaid, A. (1999) Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 457, 475-477
120. Wallace, J. L. and Del Soldato, P. (2003) The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 17, 11-20
121. Enriquez, A., Leclercq, I., Farrell, G. C. and Robertson, G. (1999) Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem. Biophys. Res. Commun. 255, 300-306
122. Barnett, C. R., Gibson, G. G., Wolf, C. R., Flatt, P. R. and Ioannides, C. (1990) Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem. J. 268, 765-769
123. Wang, M. H., Smith, A., Zhou, Y. et al. (2003) Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 42, 594-599
124. Shimojo, N., Ishizaki, T., Imaoka, S., Funae, Y., Fujii, S. and Okuda, K. (1993) Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem. Pharmacol. 46, 621-627
125. Laffer, C. L., Laniado-Schwartzman, M., Nasjletti, A. and Elijovich, F. (2004) 20-HETE and circulating insulin in essential hypertension with obesity. Hypertension 43, 388-392
126. 2+/calmodulm-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol. Res. 52, 252-257
127. Zhao, X., Dey, A., Romanko, O. P. et al. (2005) Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 288, R188-R196
128. Antonipillai, I., Nadler, J., Vu, E. J., Bughi, S., Natarajan, R. and Horton, R. (1996) A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J. Clin. Endocrinol. Metab. 81, 1940-1945
129. Hishinuma, T., Koseki, Y., Murai, Y., Yamazaki, T., Suzuki, K. and Mizugaki, M. (1999) Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. Prostaglandins Other Lipid Mediators 58, 263-271
130. Hardy, G., Stanke-Labesque, F., Peoc'h, M. et al. (2001) Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin-induced diabetic rats. Arterioscler., Thromb., Vasc. Biol. 21, 1751-1758
131. Kang, S. W., Adler, S. G., Nast, C. C. et al. (2001) 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int. 59, 1354-1362
132. Parthasarathy, S., Wieland, E. and Steinberg, D. (1989) A role for endothehal cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 86, 1046-1050
133. Scheidegger, K.J., Butler, S. and Witztum, J. L. (1997) Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J. Biol. Chem. 272, 21609-21615
134. George, J., Afek, A., Shaish, A. et al. (2001) 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104, 1646-1650
135. Harats, D., Shaish, A., George, J. et al. (2000) Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler., Thromb., Vasc. Biol. 20, 2100-2105
136. Natarajan, R., Gerrity, R. G., Gu, J. L., Lanting, L., Thomas, L. and Nadler, J. L. (2002) Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 45, 125-133
137. Gu, J. L., Pei, H., Thomas, L. et al. (2001) Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation 103, 1446-1452
138. Cyrus, T., Witztum, J. L., Rader, D. J. et al. (1999) Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103, 1597-1604
139. Natarajan, R., Gu, J. L., Rossi, J. et al. (1993) Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 90, 4947-4951
140. Patricia, M. K., Natarajan, R., Dooley, A. N. et al. (2001) Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ. Res. 88, 659-665
141. Patricia, M. K., Kim, J. A., Harper, C. M. et al. (1999) Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler., Thromb., Vasc. Biol. 19, 2615-2622
142. Natarajan, R., Gonzales, N., Lanting, L. and Nadler, J. (1994) Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension 23, 1142-1147
143. Hatley, M. E., Srinivasan, S., Reilly, K. B., Bolick, D. T. and Hedrick, C. C. (2003) Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J. Biol. Chem. 278, 25369-25375
144. Alpert, E., Gruzman, A., Totary, H., Kaiser, N., Reich, R. and Sasson, S. (2002) A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12- hydroxyeicosatetraenoic acid. Biochem. J. 362, 413-422
145. Tokuyama, Y., Sturis J., DePaoli, A. M. et al. (1995) Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44, 1447-1457
146. Reed, M. J., Meszaros, K., Entes, L. J. et al. (1999) Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes. Diabetologia 42, 102-106
147. Scribner, K. A., Gadbois, T. M., Gowri, M., Azhar, S. and Reaven, G. M. (2000) Masoprocol decreases serum triglyceride concentrations in rats with fructose-induced hypertriglyceridemia. Metab., Clin. Exp. 49, 1106-1110
148. Takahashi, K., Nammour, T. M., Fukunaga, M. et al. (1992) Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2α, in the rat. Evidence for interaction with thromboxane A2 receptors. J. Clin. Invest. 90, 136-141
149. 2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 58, 1963-1972
150. Mori, T. A., Woodman, R. J., Burke, V., Puddey, I. B., Croft, K. D. and Beilin, L. J. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radical Biol. Med. 35, 772-781
151. Lote, C. J., Harper, E. and Savage, C. O. (1996) Mechanisms of acute renal failure. Br. J. Anaesth. 77, 82-89
152. Braden, G. E., O'Shea, M. H., Mulhern, J. G. and Germain, M. J. (2004) Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol., Dial., Transplant. 19, 1149-1153
153. Chatziantoniou, C. and Papanikolaou, N. (1989) The role of prostaglandin and thromboxane synthesis by the glomeruli in the development of acute renal failure. Eicosanoids 2, 157-161
154. Sraer, J. D., Moulonguet-Dolens, E., Delarue, F., Sraer, J. and Ardaillou, R. (1981) Prostaglandin synthesis by glomeruli isolated from rats with glycerol-induced acute renal failure. Circ. Res. 49, 775-783
155. Papanikolaou, N., Peros, G., Morphake, P. et al. (1992) Does gentamicin induce acute renal failure by increasing renal TXA2 synthesis in rats? Prostaglandins Leukotrienes Essent. Fatty Acids 45, 131-136
156. Hasanoglu, E., Uluoglu, O. and Ercan, Z. S. (1991) The protective effects of Iloprost and thromboxane synthetase inhibitor, UK 38485, against glycerol-induced acute renal failure in rats. Prostaglandins Leukotrienes Essent. Fatty Acids. 43, 99-102
157. Newaz, M. A. and Oyekan, A. O. (2002) Contribution of renal oxygenases to glycerol-induced acute renal failure in the rat. J. Cardiovasc. Pharmacol. 39, 834-841
158. Moran, J. H., Mitchell, L. A., Bradbury, J. A. et al. (2000) Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol. Appl. Pharmacol. 168, 268-279
159. Fitzgerald, G. A. (2004) Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711